1 / 29

Does Aggressive Statin Therapy Reduce Coronary Atherosclerotic Plaque Lipid Content?

Does Aggressive Statin Therapy Reduce Coronary Atherosclerotic Plaque Lipid Content? Results From: Reduction in YEL low Plaque by Aggressive Lipid LOW ering Therapy ( YELLOW ) Trial. Annapoorna S Kini , PR Moreno, J Kovacic, A Limaye, ZA Ali, J Sweeny, U Baber, R Mehran, G Dangas, SK Sharma

tallys
Download Presentation

Does Aggressive Statin Therapy Reduce Coronary Atherosclerotic Plaque Lipid Content?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Does Aggressive Statin Therapy Reduce Coronary Atherosclerotic Plaque Lipid Content? Results From: Reduction in YELlow Plaque by Aggressive Lipid LOWeringTherapy(YELLOW) Trial Annapoorna S Kini, PR Moreno, J Kovacic, A Limaye, ZA Ali, J Sweeny, U Baber, R Mehran, G Dangas, SK Sharma Cardiac Catheterization Laboratory Mount Sinai Heart Mount Sinai Hospital, NY, NY

  2. Disclosures Annapoorna S. Kini – Institutional research support for the COLOR registry from InfraReDx

  3. Study Organization Principal Investigator: Annapoorna S. Kini, MD Co-PI: Pedro R. Moreno, MD DSMB: Chair- Donald Smith, MD, Mount Sinai School of Medicine (MSSM) Imaging Core Laboratory: Akiko Maehara, MD, Cardiovascular Research Foundation Data Coordination/Analysis: Usman Baber, MD, Roxana Mehran, MD, MSSM Sponsor: Mount Sinai School of Medicine

  4. Background • Multiple large RCT have shown beneficial effects of statin therapy in both primary and secondary prevention.1 • Several studies using gray-scale IVUS have demonstrated modest atherosclerotic plaque regression in non-obstructive coronary atheroma using statin therapy.2 • Whether statins modulate coronary atherosclerotic plaque composition or coronary flow physiology in obstructive lesions, and the timing for these effects remains unclear. • 4S, WOSCOPS, CARE, LIPID • REVERSAL, ASTEROID, PROSPECT, CAMELOT, STRADIVARIUS, SATURN

  5. Hypothesis High-Dose statin therapy will reduce lipid core content in severely obstructive coronary lesions in the short term (6-8 weeks), as evaluated by Near-infrared Spectroscopy . Primary outcome Change in coronary lipid core burden index (LCBI) after short-term high-dose statin therapy, as determined by Near-infrared Spectroscopy (NIRS).

  6. Near Infrared Spectroscopy - Validation Chemogram NIRS provides lipid contents based on the spectra processed by principal component analysis, and shown as lipid core burden index; LCBI (range 1~1000) for each region of interest. Chemogram Interpretation Histology Interpretation Histology Gardner et al. JACC Imaging 2008;1(5):638-48.

  7. Methods • Prospective, single-center, single blinded randomized trial in patients with multivessel, hemodynamically significant coronary lesions who were eligible for staged PCI at Mount Sinai Medical Center were screened. • Following PCI of the target lesion, remaining non-target, angiographically significant lesions were evaluated for hemodynamic significance with FFR. If FFR ≤0.8 the patient was enrolled in the study. • Baseline intracoronary imaging of the non-target lesion • Gray-scale IVUS • NIRS • Randomization - Standard of Care (Standard) versus Intensive statin therapy with Rosuvastatin 40mg daily (Aggressive).

  8. Methods Total number of patients screened: N = 779 • Generally/Clinically Excluded: N = 108 • Hypersensitivity N = 28) • Renal Insufficiency (N = 28) • Currently prescribed Crestor 40mg therapy (N = 19) • Participating in another investigational drug/device study (N = 5) • Unable to sign or withdrew informed consent (N= 28) • Angiographically Excluded: N = 487 • Normal coronaries, non-obstructive or 1 vessel CAD (N = 417) • ISR, CTO, vein graft or highly calcified lesions (N = 62) • Left main disease (N = 8) • Other Exclusions: N= 97 • FFR > 0.80 (N = 17) • PMD refused (N = 41) • Surgical or medical therapy (N = 36) • Technical issues (N = 3) Number of Subjects Randomized: N = 87

  9. Two/Three Vessel CAD (n= 87) After stenting the target vessel The non-target lesion underwent FFR FFR≤0.8 IVUS, NIRS Randomized StandardAggressive n = 43 n = 44 Continue statin the patient was taking Rosuvastatin 40 mg daily Dual antiplatelet therapy for 1 year Dual antiplatelet therapy for 1 year Follow up Cath (6-8 weeks) FFR, IVUS and NIRS repeated. If FFR ≤0.8, lesion stented and imaging repeated. If FFR > 0.8 the patient was treated medically. Imaging data analyzed by CRF Core Lab Data analysis for primary outcome analyzed by MSH independent Core Lab *Optimal medical therapy for all patients

  10. Baseline Characteristics

  11. Baseline Angiography/IVUS

  12. Baseline NIRS Parameters

  13. Percent Change in IVUS/angiographic parameters Absolute Change in Lipid Parameters

  14. Paired Analysis – Lesion LCBI P = 0.47 P = 0.0008 Baseline 400 Follow-up LCBI Absolute LCBI Reduction 200 33 0 Standard Aggressive

  15. Paired Analysis – 10mm LCBI P = 0.57 P < 0.0001 800 Baseline Follow-up 600 Absolute LCBI Reduction LCBI 400 118 200 0 Standard Aggressive

  16. Paired Analysis – 4mm LCBI 1000 P = 0.90 P < 0.0001 Baseline Follow-up 800 Absolute LCBI Reduction 600 LCBI 154 400 200 0 Standard Aggressive

  17. Case Example Lesion LCBI: 259 Max10mm LCBI: 511 Baseline Max4mm LCBI: 802 Plaque Area 5.6mm2 FFR: 0.74 Lesion LCBI: 177 Follow-up Max10mm LCBI: 289 Max4mm LCBI: 474 Plaque Area 5.5mm2 FFR: 0.78

  18. Limitations • Single-center, small sample size and lack of long-term follow-up limits evaluation for clinical events • Despite randomization and comparable baseline characteristics, there was higher baseline maximum LCBI in the 4 and 10mm analysis in the aggressive treatment group that may be a reflection of random play of chance in a small sample size.

  19. Conclusions • Aggressive lipid therapy results in significant reductions in the lipid content of coronary atherosclerotic plaque detected by NIRS in a short time frame (6-8 weeks)

  20. Conclusions • Aggressive lipid therapy results in significant reductions in the lipid content of coronary atherosclerotic plaque detected by NIRS in a short time frame (6-8 weeks) • Concordant changes in conventional parameters (i.e: coronary flow physiology [FFR] or gray-scale IVUS) were not observed.

  21. Conclusions • Aggressive lipid therapy results in significant reductions in the lipid content of coronary atherosclerotic plaque detected by NIRS in a short time frame (6-8 weeks) • Concordant changes in conventional parameters (i.e: coronary flow physiology [FFR] or gray-scale IVUS) were not observed. • These findings suggest that aggressive statin therapy modulates lipid composition of significant coronary atherosclerotic plaque, properties that may contribute to plaque stabilization and/or regression.

  22. Conclusions • Aggressive lipid therapy results in significant reductions in the lipid content of coronary atherosclerotic plaque detected by NIRS in a short time frame (6-8 weeks) • Concordant changes in conventional parameters (i.e: coronary flow physiology [FFR] or gray-scale IVUS) were not observed. • These findings suggest that aggressive statin therapy modulates lipid composition of significant coronary atherosclerotic plaque, properties that may contribute to plaque stabilization and/or regression. • A large randomized trial (YELLOW II) based on the present concept with long-term follow-up is forthcoming.

  23. Acknowledgments • Co-Investigators: • Samin Sharma • Pedro Moreno • Jason Kovacic • Mount Sinai Cath Lab: • Atul Limaye • Joseph Sweeney • George Dangas • Ziad Ali • Statistical Analysis: • Usman Baber • Trial Coordinators: • Kristen Falciglia • Asif Adam • Imaging Core Lab (CRF): • Akiko Maehara • Data Coordinating Center: • Roxana Mehran

  24. END

  25. Total number of patients enrolled: N= 87 Randomized to SOC: N= 43 Randomized to Rosuvastatin 40mg N= 44 • Baseline imaging: N = 43 • Follow-up imaging: N = 39 • Follow-up imaging not done: N = 4 • Lost to FU: 3 • PMD refused: 1 • Baseline imaging: N = 44 • Follow-up imaging: N = 42 • Follow-up imaging not done: N = 2 • Lost to FU: 2 • Paired IVUS: N= 32/43 • Paired LIPISCAN: N= 34/43 • Paired IVUS: N= 38/44 • Paired LIPISCAN: N= 38/44

  26. Adverse Events

  27. Near Infrared Spectroscopy (NIRS) NIRS provides lipid contents based on the spectra processed by algorithm and shown as lipid core burden index; LCBI (range 1~1000) for each region of interest. Proximal Chemogram Block Chemogram Wire Detection Landmark

  28. Percent Change in LCBI P = 0.04 P = 0.09 P = 0.05 Δ LCBI Standard Aggressive Lesion LCBI mLCBI/10mm mLCBI/4mm

  29. Adjusted associations between aggressive treatment and LCBI reduction

More Related